New ICD-10-PCS Codes in

3,562 codes were added to the 2018 ICD-10-PCS code set, effective October 1, 2017.

Displaying codes 3,501-3,562 of 3,562:

  • 4A11729 Monitoring of Peripheral Nervous Conductivity, Sensory, Via Natural or Artificial Opening
  • 4A1172B Monitoring of Peripheral Nervous Conductivity, Motor, Via Natural or Artificial Opening
  • 4A1174G Monitoring of Peripheral Nervous Electrical Activity, Intraoperative, Via Natural or Artificial Opening
  • 4A1174Z Monitoring of Peripheral Nervous Electrical Activity, Via Natural or Artificial Opening
  • 4A11829 Monitoring of Peripheral Nervous Conductivity, Sensory, Via Natural or Artificial Opening Endoscopic
  • 4A1182B Monitoring of Peripheral Nervous Conductivity, Motor, Via Natural or Artificial Opening Endoscopic
  • 4A1184G Monitoring of Peripheral Nervous Electrical Activity, Intraoperative, Via Natural or Artificial Opening Endoscopic
  • 4A1184Z Monitoring of Peripheral Nervous Electrical Activity, Via Natural or Artificial Opening Endoscopic
  • 4A1274Z Monitoring of Cardiac Electrical Activity, Via Natural or Artificial Opening
  • 4A1279Z Monitoring of Cardiac Output, Via Natural or Artificial Opening
  • 4A127CZ Monitoring of Cardiac Rate, Via Natural or Artificial Opening
  • 4A127FZ Monitoring of Cardiac Rhythm, Via Natural or Artificial Opening
  • 4A127HZ Monitoring of Cardiac Sound, Via Natural or Artificial Opening
  • 4A1284Z Monitoring of Cardiac Electrical Activity, Via Natural or Artificial Opening Endoscopic
  • 4A1289Z Monitoring of Cardiac Output, Via Natural or Artificial Opening Endoscopic
  • 4A128CZ Monitoring of Cardiac Rate, Via Natural or Artificial Opening Endoscopic
  • 4A128FZ Monitoring of Cardiac Rhythm, Via Natural or Artificial Opening Endoscopic
  • 4A128HZ Monitoring of Cardiac Sound, Via Natural or Artificial Opening Endoscopic
  • 4A1675Z Monitoring of Lymphatic Flow, Via Natural or Artificial Opening
  • 4A167BZ Monitoring of Lymphatic Pressure, Via Natural or Artificial Opening
  • 4A1685Z Monitoring of Lymphatic Flow, Via Natural or Artificial Opening Endoscopic
  • 4A168BZ Monitoring of Lymphatic Pressure, Via Natural or Artificial Opening Endoscopic
  • 4A1D83Z Monitoring of Urinary Contractility, Via Natural or Artificial Opening Endoscopic
  • 4A1D85Z Monitoring of Urinary Flow, Via Natural or Artificial Opening Endoscopic
  • 4A1D8BZ Monitoring of Urinary Pressure, Via Natural or Artificial Opening Endoscopic
  • 4A1D8DZ Monitoring of Urinary Resistance, Via Natural or Artificial Opening Endoscopic
  • 4A1D8LZ Monitoring of Urinary Volume, Via Natural or Artificial Opening Endoscopic
  • 5A0920Z Assistance with Respiratory Filtration, Continuous
  • 5A1D70Z Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day
  • 5A1D80Z Performance of Urinary Filtration, Prolonged Intermittent, 6-18 hours Per Day
  • 5A1D90Z Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day
  • B31U010 Fluoroscopy of Pulmonary Trunk using High Osmolar Contrast, Laser Intraoperative
  • B31U0ZZ Fluoroscopy of Pulmonary Trunk using High Osmolar Contrast
  • B31U110 Fluoroscopy of Pulmonary Trunk using Low Osmolar Contrast, Laser Intraoperative
  • B31U1ZZ Fluoroscopy of Pulmonary Trunk using Low Osmolar Contrast
  • B31UY10 Fluoroscopy of Pulmonary Trunk using Other Contrast, Laser Intraoperative
  • B31UYZZ Fluoroscopy of Pulmonary Trunk using Other Contrast
  • B31UZZZ Fluoroscopy of Pulmonary Trunk
  • XK02303 Introduction of Concentrated Bone Marrow Aspirate into Muscle, Percutaneous Approach, New Technology Group 3
  • XNS0332 Reposition of Lumbar Vertebra using Magnetically Controlled Growth Rod(s), Percutaneous Approach, New Technology Group 2
  • XNS3332 Reposition of Cervical Vertebra using Magnetically Controlled Growth Rod(s), Percutaneous Approach, New Technology Group 2
  • XNS4332 Reposition of Thoracic Vertebra using Magnetically Controlled Growth Rod(s), Percutaneous Approach, New Technology Group 2
  • XRG00F3 Fusion of Occipital-cervical Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRG10F3 Fusion of Cervical Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRG20F3 Fusion of 2 or more Cervical Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRG40F3 Fusion of Cervicothoracic Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRG60F3 Fusion of Thoracic Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRG70F3 Fusion of 2 to 7 Thoracic Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRG80F3 Fusion of 8 or more Thoracic Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRGA0F3 Fusion of Thoracolumbar Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRGB0F3 Fusion of Lumbar Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRGC0F3 Fusion of 2 or more Lumbar Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XRGD0F3 Fusion of Lumbosacral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
  • XW033A3 Introduction of Bezlotoxumab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 3
  • XW033B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
  • XW033C3 Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3
  • XW033F3 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
  • XW043A3 Introduction of Bezlotoxumab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 3
  • XW043B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
  • XW043C3 Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3
  • XW043F3 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
  • XY0VX83 Extracorporeal Introduction of Endothelial Damage Inhibitor to Vein Graft, New Technology Group 3